Intriguingly, mTOR inhibitors, such as temsirolimus and everolimus, have been proven to have secondary effects on angiogenesis in metaplastic breast cancer, suggesting that combining bevacizumab and temsirolimus/everolimus might be worthwhile for clinical trials [231]. The gene discussed is MTOR; the disease is breast carcinoma.